Shanghai ZhenGe Biotech, a Shanghai, China-based company focused on providing a macromolecular biological drug CDMO service, raised USD100M in Series C funding.
The round was led by Goldman Sachs Asset Management and Sofina with participation from Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital.
Shanghai ZhenGe Biotech Raises USD100M in Series C Funding comes via ChinaTechNews.com.
Tesla Buys More And More Lithium In China 24HTECH.ASIA
US-China trade deal: the enforcement hurdle
US controls on investment will not harm China, Yellen tells Beijing
LeEco’s Supercar Unit Raises $1.08B From Lenovo, Yingda Capital And Others
US-China trade tariffs cast shadow over cloud computing boom
Alibaba Pictures To Acquire 30% Of Chinese Movie Investment Firm Hehe Pictures
China and the US are too intertwined to keep up the trade war
Chinese telecoms giant ZTE forecasts loss for 2018
002340 格林美
Will Kwasi Kwarteng’s great gamble pay off?